Description:
The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
Active, not recruiting
Phase 1/Phase 2
Drug | Synonyms | Arms |
---|---|---|
Umbralisib | TGR-1202 | TG-1501 + Ublituximab + Umbralisib |
ublituximab | TG-1101 | TG-1501 + Ublituximab + Umbralisib |
TG-1501 | TG-1501 + Ublituximab + Umbralisib |
Name | Type | Description | Interventions |
---|---|---|---|
TG-1501 + Ublituximab + Umbralisib | Experimental | Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Umbralisib oral daily dose TG-1501 IV infusion at scheduled intervals |
|
Inclusion Criteria: - Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation - Refractory to or relapsed after at least 1 prior treatment regimen - Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 Exclusion Criteria: - Any major surgery, chemotherapy or immunotherapy within the last 14 days - Known hepatitis B virus, hepatitis C virus or HIV infection - Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP)
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Measure: | Determine Acceptable Adverse Events That Are Related to Treatment |
Time Frame: | 6 months of therapy |
Safety Issue: | |
Description: | To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities |
Measure: | Overall Response Rate |
Time Frame: | Up to 1 year |
Safety Issue: | |
Description: | The overall response rate (ORR) in patients with CLL and Richter's Transformation treated with Ublituximab in combination with Umbralisib and Targeted Immunotherapy |
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | TG Therapeutics, Inc. |
August 23, 2021